Trial record 1 of 1 for:    NCT01690195
Previous Study | Return to List | Next Study

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

This study has been terminated.
(Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.)
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01690195
First received: September 19, 2012
Last updated: March 21, 2014
Last verified: March 2014
  Purpose

This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.


Condition Intervention Phase
Alzheimer's Disease
Drug: ABT-126
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study

  • Laboratory Data [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Assessments include hematology, clinical chemistry, urinalysis and urine drug/alcohol screens

  • Vital Signs [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Assessments include pulse, blood pressure and oral body temperature

  • Physical examinations [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    An examination of bodily functions and physical condition

  • Brief Neurological examination [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Assessments include cranial nerves, motor and sensory system, reflexes, coordination, gait and station

  • Brief Psychiatric assessments [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Assessments include mood, anxiety, psychosis or delusions, agitation, homicidal thoughts or behaviors

  • Columbia-Suicide Severity Rating Scale [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    The scale is designed to assess suicidal behavior and ideation

  • Cornell Scale for Depression in Dementia [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Assesses the signs and symptoms of major depression in patients with dementia

  • Electrocardiogram [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
    Measurements include heart rate, RR interval, PR interval, QRS duration and QT intervals


Enrollment: 343
Study Start Date: September 2012
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ABT-126
ABT-126 Open-label dose
Drug: ABT-126
See arm description

Detailed Description:

This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study M11-793. Up to 420 subjects may participate at approximately 40 sites in seven countries.

  Eligibility

Ages Eligible for Study:   55 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.
  • The subject was randomized into Study M11-793 and completed dosing through Week 24 in that study.
  • With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG.
  • If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study drug. However, if the male subject's partner has been postmenopausal for at least two years or is surgically sterile, then use of a barrier method of birth control is not required.
  • The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.
  • The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures.

Exclusion Criteria:

  • The subject experienced an adverse event or abnormal finding in physical examination, vital signs, laboratory profile and/or ECG measurements in Study M11-793 that indicates the subject could become medically unstable during the current study.
  • The subject is currently taking or is expected to be prescribed any excluded medications without the approval of Abbott medical monitor.
  • The subject was noncompliant with donepezil or rivastigmine during Study M11-793 or is expected to discontinue these medications prior to conclusion of this study.
  • The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
  • The subject is currently enrolled in, or plans to participate in, another experimental study during the course of this trial.
  • The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in this study.
  • For any other reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01690195

  Hide Study Locations
Locations
United States, California
Site Reference ID/Investigator# 84185
Long Beach, California, United States, 90806
Site Reference ID/Investigator# 84183
San Francisco, California, United States, 94109-4841
United States, Connecticut
Site Reference ID/Investigator# 84187
Hamden, Connecticut, United States, 06518
United States, Florida
Site Reference ID/Investigator# 84178
Delray Beach, Florida, United States, 33445
Site Reference ID/Investigator# 84180
Orlando, Florida, United States, 32806
Site Reference ID/Investigator# 84186
West Palm Beach, Florida, United States, 33407
United States, Illinois
Site Reference ID/Investigator# 84182
Elk Grove Village, Illinois, United States, 60007
United States, New York
Site Reference ID/Investigator# 84181
Staten Island, New York, United States, 10312
United States, Vermont
Site Reference ID/Investigator# 84179
Bennington, Vermont, United States, 05201
Canada
Site Reference ID/Investigator# 84173
Gatineau, Canada, J9A 1K7
Site Reference ID/Investigator# 84174
Montreal, Canada, H3T 1E2
Site Reference ID/Investigator# 84177
Peterborough, Canada, K9H 2P4
Site Reference ID/Investigator# 84175
Toronto, Canada, M3B 2S7
Site Reference ID/Investigator# 84176
Verdun, Canada, H4H 1R3
France
Site Reference ID/Investigator# 84376
Dijon Cedex, France, 21033
Site Reference ID/Investigator# 84373
Limoges Cedex, France, 87042
Site Reference ID/Investigator# 84377
Paris, France, 75013
Site Reference ID/Investigator# 84374
Paris Cedex 10, France, 75475
Site Reference ID/Investigator# 84375
Toulouse Cedex 9, France, 31059
Germany
Site Reference ID/Investigator# 84382
Berlin, Germany, 14050
Site Reference ID/Investigator# 84380
Freiburg, Germany, 79106
Site Reference ID/Investigator# 84383
Huettenberg, Germany, 35625
Site Reference ID/Investigator# 84379
Mittweida, Germany, 09648
Site Reference ID/Investigator# 84381
Munich, Germany, 81675
Site Reference ID/Investigator# 84378
Schwerin, Germany, 19053
Greece
Site Reference ID/Investigator# 84385
Athens, Greece, 115 21
Site Reference ID/Investigator# 84388
Athens, Greece, 151 25
Site Reference ID/Investigator# 84389
Athens, Greece, 15123
Site Reference ID/Investigator# 84386
Haidari, Athens, Greece, 12462
Site Reference ID/Investigator# 84390
Thessaloniki, Greece, 570 10
South Africa
Site Reference ID/Investigator# 84395
Belville, South Africa, 7530
Site Reference ID/Investigator# 84391
Cape Town, South Africa, 7405
Site Reference ID/Investigator# 84393
George, South Africa, 6529
Site Reference ID/Investigator# 84394
Johannesburg, South Africa, 2196
Site Reference ID/Investigator# 84392
Rosebank, South Africa, 2196
United Kingdom
Site Reference ID/Investigator# 84398
Bath, United Kingdom, BA1 3NG
Site Reference ID/Investigator# 84397
Glasgow, United Kingdom, G20 0XA
Site Reference ID/Investigator# 84400
London, United Kingdom, TW8 8DS
Site Reference ID/Investigator# 84399
Manchester, United Kingdom, M8 5RB
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
Study Director: Laura Gault, MD AbbVie
  More Information

No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT01690195     History of Changes
Other Study ID Numbers: M11-428, 2012-000537-39
Study First Received: September 19, 2012
Last Updated: March 21, 2014
Health Authority: United States: Food and Drug Administration
South Africa: Medicines Control Council
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Canada: Health Canada
France: Afssaps - Agence francaise de securite sanitaire des produits de sante (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Greece: National Organization of Medicines

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Cholinesterase Inhibitors
Cholinergic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 23, 2014